Finite State vs MedCrypt
Both help medical device manufacturers meet FDA cybersecurity obligations, and both grade A on regulatory status and model transparency, so the question is where each starts. Finite State starts from the shipped artifact: it unpacks the binary itself across a reported 130 plus formats without source code access, deriving the true component inventory rather than trusting a supplied SBOM, which is decisive for the third party and off the shelf components manufacturers cannot inspect. MedCrypt starts from the submission: it maps precisely to the enforceable obligations under Section 524B and names its exploitability sources openly, and it is candid that its core is a rules engine over public feeds rather than a model. The honest divide is analytical depth against regulatory framing. If your failure mode is not knowing what is actually inside your firmware, start with Finite State, and ask it to validate its not affected reachability calls. If your failure mode is assembling a defensible FDA submission from transparent inputs, start with MedCrypt.
- It does not trust the SBOM it is handed: the platform unpacks the shipped artifact itself across a reported 130 plus binary formats and 30 plus architectures, revealing libraries and components inside encrypted or proprietary firmware without source code access, which is exactly where unknown risk accumulates.
- The most technically specific disclosure in the category, graded A on model transparency: binary composition analysis extracting control flow graphs and symbols, static analysis of decompiled code, and reachability analysis over call graphs, so a security engineer can judge whether it would work on their firmware from the description alone.
- Wider lifecycle and market coverage, graded A on setting: design through postmarket in one system of record, with regulatory mapping extending beyond FDA Section 524B to the EU Cyber Resilience Act.
- The clearest regulatory literacy in the lane, graded A: the product maps directly to the enforceable obligations under Section 524B, from SBOM minimum elements to per vulnerability risk assessments and postmarket monitoring, and the company publishes analysis of actual FDA premarket deficiency patterns.
- Auditable inputs rather than proprietary intelligence, graded A on model transparency: exploitability is built explicitly on EPSS, CISA KEV, ExploitDB, Metasploit, NVD, and CWE Top 25, all sources a buyer can evaluate independently, which almost nothing else in this lane permits.
- Honest about its own mechanism: MedCrypt's core is a rules engine over curated public feeds rather than a model, graded C on AI centrality, so what you buy is regulatory framing and transparency, not model quality.
Side-by-Side
| Axis | F Finite State |
M MedCrypt |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | ||
| Model and Technology Transparency | ||
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | ||
| HIPAA and BAA Posture | ||
| Security Certifications and Trust Center | ||
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | ||
| EHR and Interoperability Depth | ||
| Deployment Model and Data Residency | ||
| Commercial Transparency | ||
| Setting and Specialty Coverage |
This is the manufacturer side contrast pair, and both vendors grade A on FDA and regulatory status and on model transparency, so the split is method rather than compliance. Finite State grades B on AI centrality because its depth is program analysis rather than machine learning, still genuinely the product; MedCrypt grades C because its core is a rules engine over public feeds, which the index states plainly. Finite State grades C on governance for a specific reason worth weighing: reachability analysis is used to justify NOT remediating a vulnerability, so a false negative produces a documented regulatory justification for leaving an exploitable flaw in a shipped device, a higher consequence error than over alerting. Both vendors' performance claims are self generated case studies, graded C on evidence, and neither publishes a security attestation despite holding a complete map of customers' firmware. Neither processes PHI. Neither publishes pricing.